Topical administration of cyclosporin A in a solid lipid nanoparticle formulation
- Authors
- Kim, Sung Tae; Jang, Dong-Jin; Kim, Jong Hyo; Park, Joo Yeon; Lim, Ji Soo; Lee, So Yeon; Lee, Kyung-Mi; Lim, Soo-Jeong; Kim, Chong-Kook
- Issue Date
- Aug-2009
- Publisher
- GOVI-VERLAG PHARMAZEUTISCHER VERLAG GMBH
- Keywords
- ATOPIC-DERMATITIS; TRANSDERMAL DELIVERY; TACROLIMUS; SLN; THERAPY; IL-4; SIZE; SKIN
- Citation
- PHARMAZIE, v.64, no.8, pp 510 - 514
- Pages
- 5
- Indexed
- SCIE
SCOPUS
- Journal Title
- PHARMAZIE
- Volume
- 64
- Number
- 8
- Start Page
- 510
- End Page
- 514
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/119605
- DOI
- 10.1691/ph.2009.8373
- ISSN
- 0031-7144
- Abstract
- Cyclosporin A (CsA)-loaded solid lipid nanoparticles (SLN) were developed for improved skin penetration. CsA-loaded SLN, prepared using a hot homogenization method, were nano-sized (about 73 nm) with a slightly negative surface charge (about - 16 mV) and stable under physiological conditions regardless of CsA incorporation. In vitro permeation studies using murine skin mounted in the Franz-type vertical diffusion assembly revealed that the skin permeation efficiency of CsA-loaded SLN was 2-fold higher than that of CsA-oil mixture in viable skin. Furthermore, topically administered CsA-loaded SLN relieved symptoms of atopic dermatitis (AD) in an in vivo murine model of AD by decreasing the T helper (Th) 2 cell-related cytokines interleukin (IL)-4 and -5. These results suggest that SLN are effective drug carriers for topical delivery and that CsA-loaded SLN can be therapeutically applied in allergy-related skin disorders.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.